BORA Trademark

Trademark Overview


On Wednesday, November 4, 2020, a trademark application was filed for BORA with the United States Patent and Trademark Office. The USPTO has given the BORA trademark a serial number of 90298508. The federal status of this trademark filing is REGISTERED as of Tuesday, March 21, 2023. This trademark is owned by BORA PHARMACEUTICALS CO., LTD.. The BORA trademark is filed in the Pharmaceutical Products category with the following description:

Nutritional supplements; Antiallergic medicines; Sulphonamides as medicines; Medicines for intestinal disorders; Medicines for dental purposes; Medicines for alleviating constipation; Motion sickness medicines; Medicines for the treatment of gastrointestinal diseases; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Ocular pharmaceuticals; Antibacterial pharmaceuticals; Cardiovascular pharmaceuticals; Anti-diabetic pharmaceuticals; Pharmaceuticals, namely, psychotropics; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, inducers of erections; Injectable pharmaceuticals for treatment of anaphylactic reactions; Pharmaceuticals, namely, lipid loweri...
bora

General Information


Serial Number90298508
Word MarkBORA
Filing DateWednesday, November 4, 2020
Status700 - REGISTERED
Status DateTuesday, March 21, 2023
Registration Number7002927
Registration DateTuesday, March 21, 2023
Mark Drawing5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, January 3, 2023

Trademark Statements


Description of MarkThe mark consists of the stylized letters "BORA".
Goods and ServicesNutritional supplements; Antiallergic medicines; Sulphonamides as medicines; Medicines for intestinal disorders; Medicines for dental purposes; Medicines for alleviating constipation; Motion sickness medicines; Medicines for the treatment of gastrointestinal diseases; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Ocular pharmaceuticals; Antibacterial pharmaceuticals; Cardiovascular pharmaceuticals; Anti-diabetic pharmaceuticals; Pharmaceuticals, namely, psychotropics; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, inducers of erections; Injectable pharmaceuticals for treatment of anaphylactic reactions; Pharmaceuticals, namely, lipid lowering agents; Antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals; Astringents for medicinal purposes; Pharmaceutical preparations for wounds; Dermatological pharmaceutical products; Pharmaceutical skin lotions; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for skin care; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations for use in urology; Pharmaceutical products and preparations for chloasma; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for treating diabetes; Pharmaceutical solutions used in dialysis; Pharmaceutical products for ophthalmological use; Anti-epileptic pharmaceutical preparations; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating hypertension; Pharmaceutical antitussive-cold preparations; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for skin wounds; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating halitosis; Effervescent analgesic pharmaceutical preparations; Pharmaceutical products for the prevention and treatment of cancer; Analgesic and muscle relaxant pharmaceutical preparations; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting sensory organs; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical products for treating respiratory diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products for the treatment of joint disease; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the relief of insect bites; Pharmaceutical preparations for the treatment of bone fractures; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for treating allergic rhinitis; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, January 4, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBORA PHARMACEUTICALS CO., LTD.
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressTaipei City 11491
TW

Party NameBORA PHARMACEUTICALS CO., LTD.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressTaipei City 11491
TW

Party NameBORA PHARMACEUTICALS CO., LTD.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressTaipei City 11491
TW

Trademark Events


Event DateEvent Description
Tuesday, March 21, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, March 21, 2023REGISTERED-PRINCIPAL REGISTER
Tuesday, January 3, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 3, 2023PUBLISHED FOR OPPOSITION
Wednesday, December 14, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, November 30, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 9, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, November 9, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, November 8, 2022ASSIGNED TO LIE
Tuesday, November 1, 2022TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Monday, May 16, 2022NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, May 16, 2022LETTER OF SUSPENSION E-MAILED
Monday, May 16, 2022SUSPENSION LETTER WRITTEN
Monday, May 16, 2022ASSIGNED TO EXAMINER
Thursday, May 12, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 12, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 12, 2022ASSIGNED TO LIE
Tuesday, May 10, 2022TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Saturday, December 11, 2021NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Saturday, December 11, 2021INQUIRY TO SUSPENSION E-MAILED
Saturday, December 11, 2021SUSPENSION INQUIRY WRITTEN
Monday, November 22, 2021SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION
Thursday, May 20, 2021NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, May 20, 2021LETTER OF SUSPENSION E-MAILED
Thursday, May 20, 2021SUSPENSION LETTER WRITTEN
Thursday, April 29, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, April 28, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 28, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, April 10, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, April 10, 2021NON-FINAL ACTION E-MAILED
Saturday, April 10, 2021NON-FINAL ACTION WRITTEN
Friday, April 9, 2021ASSIGNED TO EXAMINER
Monday, January 4, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, November 7, 2020NEW APPLICATION ENTERED